Axsome Therapeutics' Key Drug Candidate Whiffs in Phase 3 Trial

Axsome Therapeutics (NASDAQ:AXSM) on Monday released the data from its phase 3 trial for AXS-05 in patients suffering from treatment-resistant depression (TRD), and it was not quite what the company had hoped for. AXS-05 failed to achieve its primary endpoint in the study, although it did show efficacy in its secondary endpoint.